Global pharmaceutical company Eli Lilly & Co. NYSE: LLY has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been going heads-up against GLP-1 leader Novo Nordisk A/S NYSE: NVO, best known for Ozempic and Wegovy.Eli Lilly and Company TodayLLYEli Lilly and Company$918.00 +3.43 (+0.38$434.34▼$928.60Dividend Yield0.57$816.78Add to WatchlistBy all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is ...